Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01416402 · ClinicalTrials.gov registry record · Phase 2
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01416402 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 27 participants.
The verdict
NCT01416402, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether arhalofenate is safe and effective when dosed in combination with febuxostat in lowering serum uric acid in patients with gout.
Interventions
- DRUG Colchicine
- DRUG Febuxostat
- DRUG Arhalofenate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-08 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01416402
The ClinicalTrials.gov registry entry for NCT01416402 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Colchicine is the first listed.
NCT01416402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01416402 about?
NCT01416402 is a clinical study titled "Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients". The purpose of this study is to determine whether arhalofenate is safe and effective when dosed in combination with febuxostat in lowering serum uric acid in patients with gout.
What is the current status of trial NCT01416402?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2011-08. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01416402?
The interventions under investigation include: Colchicine (DRUG), Febuxostat (DRUG), Arhalofenate (DRUG).
Who is sponsoring clinical trial NCT01416402?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.